thalidomide has been researched along with Restless Legs Syndrome in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Restless Legs Syndrome: A disorder characterized by aching or burning sensations in the lower and rarely the upper extremities that occur prior to sleep or may awaken the patient from sleep.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent developments in the genetics of restless legs syndrome (RLS) revealed associations of disease risk with genetic loci containing the genes coding cereblon, the protein bound by thalidomide, and its endogenous substrate MEIS2, whose degradation is inhibited by the thalidomide-cereblon interaction." | 7.96 | Therapeutic effectiveness of thalidomide in a patient with treatment-resistant restless legs syndrome. ( Oexle, K; Salminen, AV; Schandra, N; Schormair, B; Winkelmann, J, 2020) |
| "Recent developments in the genetics of restless legs syndrome (RLS) revealed associations of disease risk with genetic loci containing the genes coding cereblon, the protein bound by thalidomide, and its endogenous substrate MEIS2, whose degradation is inhibited by the thalidomide-cereblon interaction." | 3.96 | Therapeutic effectiveness of thalidomide in a patient with treatment-resistant restless legs syndrome. ( Oexle, K; Salminen, AV; Schandra, N; Schormair, B; Winkelmann, J, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salminen, AV | 1 |
| Schandra, N | 1 |
| Schormair, B | 1 |
| Oexle, K | 1 |
| Winkelmann, J | 1 |
1 other study available for thalidomide and Restless Legs Syndrome
| Article | Year |
|---|---|
Therapeutic effectiveness of thalidomide in a patient with treatment-resistant restless legs syndrome.
Topics: Female; Humans; Restless Legs Syndrome; Thalidomide | 2020 |